title: The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma.
abstract: BACKGROUND
  IVX-0142 is a heparin-derived hypersulfated disaccharide devoid of anticoagulant activity while possessing anti-allergic and anti-inflammatory activity in preclinical studies. In a proof-of-concept study, the allergen inhalation challenge model was used to investigate the effect of IVX-0142 in mild atopic asthma.
  
  
  METHODS
  Nineteen subjects, not on controller medications, were randomized to an evaluator-blind, placebo-controlled, cross-over study. The effect of a single nebulized dose of IVX-0142 (80 mg) or placebo administered 30 min prior to allergen inhalation was evaluated on the allergic airway responses, airway responsiveness, and airway inflammation.
  
  
  RESULTS
  When compared with placebo, 14 and 13 subjects experienced a relatively smaller maximum fall in forced expiratory volume in 1 s (maxFEV(1)%) for the early airway response (EAR) and late airway response (LAR) with IVX-0142, respectively (P < 0.01). The degree of attenuation in the EAR [maxFEV(1)% (mean +/- SE) 26.5 +/- 2.8%vs placebo 31.0 +/- 2.8%, P = 0.059] and LAR (15.6 +/- 2.9%vs placebo 19.0 +/- 2.9%, P = 0.24) with IVX-0142, however, was small and did not reach statistical significance compared with placebo. Similarly, a trend in the attenuation of allergen-induced increase in the absolute sputum cell counts was also observed. No difference in the allergen-induced increase in airway hyper-responsiveness and exhaled nitric oxide was noticed.
  
  
  CONCLUSIONS
  The majority of mild atopic asthmatics demonstrated a reduction in the EAR and LAR to IVX-0142. However, the treatment effect observed with a single prechallenge dose of IVX-0142 was small and heterogeneous. The potential anti-allergic and anti-inflammatory effects using multiple higher doses need to be evaluated.
authors.affiliation: Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Duong
authors.forename: D
authors.initials: D
authors.lastname: Cockcroft
authors.forename: L-P
authors.initials: LP
authors.lastname: Boulet
authors.forename: T
authors.initials: T
authors.lastname: Ahmed
authors.forename: H
authors.initials: H
authors.lastname: Iverson
authors.forename: D C
authors.initials: DC
authors.lastname: Atkinson
authors.forename: E G
authors.initials: EG
authors.lastname: Stahl
authors.forename: R
authors.initials: R
authors.lastname: Watson
authors.forename: B
authors.initials: B
authors.lastname: Davis
authors.forename: J
authors.initials: J
authors.lastname: Milot
authors.forename: G M
authors.initials: GM
authors.lastname: Gauvreau
authors.forename: P M
authors.initials: PM
authors.lastname: O'Byrne
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D018592:Cross-Over Studies; D004187:Disaccharides / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D004187:Disaccharides; C534369:IVX-0142